A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of Cariprazine(RGH-188) in the Prevention of Relapse in Patients With Schizophrenia.

Trial Profile

A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of Cariprazine(RGH-188) in the Prevention of Relapse in Patients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 08 Mar 2017 According to a Allergan media release, the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data from this study to the current product label.
    • 29 Mar 2016 According to a Gedeon Richter media release, the EMA has accepted the company's regulatory submission for cariprazine the treatment of schizophrenia in adult patients.
    • 25 Aug 2015 According to an Allergan media release, data from this study will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top